Is Pluri Inc. (PLUR) a Buy, Sell, or Hold?
Pluri Inc.
NASDAQ:PLUR
$5.043 USD
-$0.06 (-1.12%)
- Volume
- 5.08K
- Average Volume
- 25.9K
- Market Capitalization
- $28.03M
- P/E Ratio
- -1.21
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $8.48
- Year Low
- $3.76
- Payout Ratio
- $0.00
- Current Ratio
- $5.90
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Market |
| CEO | Mr. Yaacov Yanay |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PLUR |
| CUSIP | 72942G104 |
| CIK | 0001158780 |
| Web | https://pluri-biotech.com/ |
| Phone | 972 7 4710 8600 |
| Currency | USD |
| Employees | 106 |
| Country | IL |
Liquidity
| Debt-to-Equity Ratio | -4.91 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.90 |
| Quick Ratio | 5.90 |
| Cash Ratio | 0.78 |
Sales & Book Value
| Annual Sales | $326K |
| Price / Sales | 46.88 |
| Cash Flow | -3.18 |
| Price / Cash Flow | -1.68 |
| Price / Book | -5.00 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.99 |
| Trailing P/E Ratio | -1.21 |
| PEG Ratio | 0.03 |
| P/E Growth | 0.03 |
| Net Income | $-20.89M |
| Net Margin | -3661.87% |
| Pretax Margin | -3726.09% |
| Return on Equity | 7656.64% |
| Return on Assets | -61.79% |
Financials Score
| AltmanZ Score | -17.58 |
| Piotroski Score | 3.00 |
| Working Capital | 22.45M |
| Total Assets | 35.44M |
| Ebit | -21.41M |
| Market Cap | 28.03M |
| Total Liabilities | 35.5M |
Poll Results
About Pluri Inc. (NASDAQ:PLUR) Stock
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly k ... nown as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event
2024-11-12 13:00:00
HAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
2024-11-11 06:00:00
Memorandum of Understanding has been signed NEW YORK , Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facility upon finalizing the binding definitive agreement.
Plurilock Corporate Update for Shareholders
2024-07-23 07:00:00
CEO Ian L. Paterson will host a webinar and Q&A Tuesday July 23, 2024, at 1pm ET / 10am PT Announced over $20 million of new business since the beginning of the year Growth in Critical Services business driving margin expansion Oversubscribed $5.5 million financing, warrant exercises, debt conversion fortifies balance sheet Attracting top industry talent for next phase of growth Vancouver, British Columbia--(Newsfile Corp. - July 23, 2024) - Purilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a global cybersecurity services and solutions provider, announces a corporate update. Plurilock Corporate Update Webinar Plurilock Security CEO Ian L.
Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates
2024-07-18 02:30:00
PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companies PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companies
2024-06-18 06:30:00
HAIFA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced strategic investments in Pluri's subsidiary, Ever After Foods Ltd. (“Ever After Foods”), which offers a cutting-edge technology platform to produce cultivated food with unmatched, cost-efficient scalability. Ever After Foods is Pluri's majority-owned joint venture with Israeli food giant Tnuva Food-Tech Incubator (2019), L.P. (“Tnuva”), and has exclusive licensing rights to use Pluri's technology and intellectual property to develop, manufacture and commercialize cultivated meat. The $10 million funding round will propel Ever After Foods' cost-advantageous and scalable technology platform, positioning it as a leading technology enabler.
Frequently Asked Questions
-
What is the current Pluri Inc. (PLUR) stock price?
-
Pluri Inc.(NASDAQ:PLUR) stock price is $5.043 in the last trading session. During the trading session, PLUR stock reached the peak price of $8.48 while $3.76 was the lowest point it dropped to. The percentage change in PLUR stock occurred in the recent session was --1.12% while the dollar amount for the price change in PLUR stock was -$-0.06.
-
PLUR's industry and sector of operation?
-
The NASDAQ listed PLUR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PLUR?
-
Mr. Yaacov Yanay | President, Chief Executive Officer & Director
Ms. Efrat Livne-Hadass | Chief Wellbeing Officer
Mr. John Dvor | EVice President North America
Ms. Orly Amiran | Chief Quality Officer
Dr. Arthur Machlenkin Ph.D. | Chief Scientific Officer -
How many employees does PLUR have?
-
Number of PLUR employees currently stands at 106. PLUR operates from Building No. 5, Haifa, None 3508409, IL.
-
Link for PLUR official website?
-
Official Website of PLUR is: https://pluri-biotech.com/
-
How do I contact PLUR?
-
PLUR could be contacted at phone #972 7 4710 8600 and can also be accessed through its website. PLUR operates from Building No. 5, Haifa, None 3508409, IL.
-
How many shares of PLUR are traded daily?
-
The average number of PLUR shares traded daily for last 3 months was 25.9K.
-
What is the market cap of PLUR currently?
-
The market value of PLUR currently stands at $28.03M with its latest stock price at $5.043